Loading...
Please wait, while we are loading the content...
Similar Documents
miR-373 promotes neuroblastoma cell proliferation, migration, and invasion by targeting SRCIN1
| Content Provider | Scilit |
|---|---|
| Author | Yuan, Xiu-Li Wen, Fei-Qiu Chen, Xiao-Wen Jiang, Xian-Ping Liu, Si-Xi |
| Copyright Year | 2019 |
| Description | Journal: OncoTargets and therapy Introduction: Previous studies have shown that miR-373 functions as either a tumor suppressor or an oncogene depending on which type of cancer it's operating in. However, the functional role of miR-373 in neuroblastoma (NB) remains largely unclear. Methods: Expression of miR-373 and SRC kinase signaling inhibitor 1 (SRCIN1) in 20 metastatic and 20 primary NB tissues was detected by quantitative real-time PCR (qRT-PCR) and Western blotting. MTT assay, flow cytometry analysis and transwell migration and invasion assays were performed to evaluate the influence of miR-373 inhibition on the growth, migration and invasion of NB cells, respectively. In vivo experiment was applied to determine the effect of miR-373 inhibition on tumor growth. Dual-luciferase reporter assay was used to confirm the interaction between miR-373 and SRCIN1. Results: We observed a significant increase in the expression of miR-373 in metastatic NB samples compared with primary NB samples, and this was inversely correlated with SRCIN1 expression. Functional studies revealed that depletion of miR-373 inhibited in vitro NB cell growth, migration and invasion, and also suppressed tumor growth in an in vivo mouse model. Moreover, we identified that SRCIN1 was a direct and functional target gene of miR-373. Silencing of SRCIN1 partially rescued the antimiR-373-mediated inhibition of cell growth, migration and invasion. Conclusion: The data from our study verified a potential oncogenic role of miR-373 in NB cells that occurs through direct targeting SRCIN1. The newly identified miR-373/SRCIN1 axis represents a new potential candidate for therapeutic intervention of malignant NB. |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593744/pdf https://www.dovepress.com/getfile.php?fileID=50652 |
| Ending Page | 4936 |
| Page Count | 10 |
| Starting Page | 4927 |
| ISSN | 11786930 |
| DOI | 10.2147/ott.s205582 |
| Journal | OncoTargets and therapy |
| Volume Number | ume 12 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 2019-06-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: OncoTargets and therapy |
| Content Type | Text |
| Subject | Pharmacology (medical) Oncology |
